Nursing implications in the administration of paclitaxel (TAXOL).
Paclitaxel is an antimicrotubule agent that was recently approved by the Food and Drug Administration (FDA). Because it is insoluble in water, it is mixed with Cremophor EL (polyoxyethylated castor oil). The addition of Cremophor requires the use of glass bottles or polyolefin or polypropylene bags and polypropylene-lined tubings for the administration of paclitaxel. In addition, 0.22 micron in-line filters are necessary. The potential side effects of paclitaxel during its infusion include hypersensitivity reaction (HSR), cardiotoxicity, infiltration, diarrhea, and nausea, whereas myelosuppression, neurotoxicity, myalgias, arthralgias, alopecia, fatigue, headache, taste changes, and minor alterations in renal and liver function tests can occur after its administration. Premedications including an H2 blocker, a corticosteroid, and an antihistamine are necessary to minimize the occurrences of HSRs. Vital signs should be monitored throughout the infusion to assess for HSRs and cardiotoxicity. Paclitaxel has been shown to be safe in both the inpatient and outpatient settings. Nursing care includes the administration of the drug, the assessment and management of side effects, and psychosocial support of patients receiving the drug.
Rogers
B B
BB
Clinical Studies Unit, Fox Chase Cancer Center, Philadelphia, PA 19111.
D004358:Drug Therapy / Q000451:nursing* / Q000523:psychology; D006801:Humans; D008991:Monitoring, Physiologic / Q000451:nursing; D009859:Oncology Nursing; D017239:Paclitaxel / Q000009:adverse effects*; D010347:Patient Care Planning; D010353:Patient Education as Topic
D017239:Paclitaxel